OKLAHOMA CITY, April 23, 2018 -- Federman & Sherwood announces that on April 20, 2018, a class action lawsuit was filed in the United States District Court for the District of Utah against Myriad Genetics, Inc. (NASDAQ:MYGN). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is August 13, 2014 through March 12, 2018.
Plaintiff seeks to recover damages on behalf of all Myriad Genetics, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, June 19, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:
Robin Hester
FEDERMAN & SHERWOOD
10205 North Pennsylvania Avenue
Oklahoma City, OK 73120
Email to: [email protected]
Or, visit the firm’s website at www.federmanlaw.com


Meta, U.S. States Discuss Settlement in Teen Addiction Trial
SK Hynix Shares Fall as Workers Reject Wage Deal
Tesla Raises Cybertruck Prices by $5,000 in US
Luxshare Shares Rise as First-Half Profit Jumps 18%
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Nvidia Options Price in $280 Billion Earnings Swing
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
Bathla Group Hires Administrators as Australia Housing Slump Deepens
Trump Buys SpaceX Shares After Record IPO
Mercer International Stock Surges 45% on C$20 Million Canada Funding
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
OpenAI AI Agent Swarm Behind Hugging Face Hack
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 



